Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06281405

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer

TORCH-iTNT is a prospective, multicentre, randomized phase II trial. 198 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B (1:1). Group A receives 6 cycles of Toripalimab combined with CAPOX (ToriCAPOX). Group B receives SCRT (25Gy/5Fx) followed by 6 cycles of ToriCAPOX. TME surgery is scheduled after TNT while a watch and wait (W&W) option can be applied to patients achieving clinical complete response (cCR). The primary endpoint is complete response (CR, pathological complete response [pCR] plus cCR) rate. The secondary endpoints include the grade 3-4 acute adverse effects (AE) rate, organ or anal preservation rate, 3-year DFS rate, etc.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Fudan University Shanghai Cancer Center

Shanghai, China

Location status: Recruiting

Location contact

Zhen Zhang, MD, PHD

CONTACT

[email protected]

18801735029

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-70 years old, female and male;
  • Pathological confirmed adenocarcinoma;
  • The distance from anal verge ≤ 10 cm;
  • MSI/MMR status: MSS/pMMR;
  • Clinical stage T3-4 and/or N+, without distance metastases;
  • At least one of the following factors is present: distance from the anus ≤5 cm, cT4, cN2, positive cMRF, positive cEMVI, or positive lateral lymph nodes;
  • KPS ≥ 70;
  • No radiotherapy, chemotherapy, immunotherapy, or any other anti-tumor therapy had been administered prior to enrollment;
  • Baseline blood and biochemical indicators meet the following criteria: neutrophils ≥ 1.5 × 10^9/L, Hb ≥ 90 g/L, PLT ≥ 100 × 10^9/L, ALT/ AST ≤ 2.5 ULN, Cr ≤ 1 ULN;
  • With good compliance and signed the consent form.

Exclusion criteria

  • Pregnancy or breast-feeding women;
  • Known history of other malignancies within 5 years;
  • Known history of severe neurological or mental illness (such as schizophrenia, dementia or epilepsy);
  • Current severe cardiac disease (cardiac dysfunction and arrhythmia), renal dysfunction and liver dysfunction;
  • Acute cardiac infarction or cerebral ischemic stroke occurred within 6 months before recruitment;
  • Uncontrolled infection which needs systemic therapy;
  • Active autoimmune disease or immunodeficiencies, known history of organ transplantation or systematic use of immunosuppressive agents;
  • Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1 to 2 antibody positive), active syphilis infection, active pulmonary tuberculosis infection;
  • Allergic to any component of the therapy.

Treatment and study plan

PD-1 inhibitor

Drug

PD-1 inhibitor (Toripalimab): 240mg d1 q3w

Other names: Toripalimab

Capecitabine

Drug

Capecitabine: 1000mg/m2 bid d1-14 q3w

Short-course radiotherapy

Radiation

Short-course radiotherapy: 25Gy/5Fx

Oxaliplatin

Drug

Oxaliplatin 130mg/m2 d1 q3w

Primary outcomes

  1. Complete response (CR) rate

    Time frame: 1 month after the surgery or the decision of W&W

    Rate of complete response (CR), including the rate of pathologic complete response (pCR) after surgery and the rate of cCR with W&W strategy.

Secondary outcomes

  1. Grade 3-4 adverse effects rate

    Time frame: From date of randomization until 3 months after the completion neoadjuvant therapy

    Rate of chemotherapy, radiotherapy and immunotherapy related adverse events

  2. 3 year organ or anal preservation rate

    Time frame: From date of randomization until the resection of rectum or anus, assessed up to 36 months.

    3 year organ or anal preservation rate

  3. 3 year disease free survival rate

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.

    Rate of 3 year disease free survival

  4. 3 year local recurrence free survival rate

    Time frame: From date of randomization until the date of first documented pelvic failure, assessed up to 36 months.

    Rate of 3 year local recurrence free survival

  5. 3 year distant metastasis free survival rate

    Time frame: From date of randomization until the date of first documented distant metastasis, assessed up to 36 months.

    Rate of 3 year distant metastasis free survival

  6. 3 year overall survival rate

    Time frame: From date of randomization until the date of death from any cause, assessed up to 36 months.

    Rate of 3 year overall survival

  7. Rate of surgical complications

    Time frame: The surgical complications were assessed within 3 months after the surgery.

    Rate of surgical complications, such as intraoperative hemorrhage, anastomotic leakage, intestinal obstruction, etc.

Study contacts

Contact information is provided by the study sponsor or research team.

Yaqi Wang, MD

CONTACT

[email protected]

18121299593

Zhen Zhang, MD

CONTACT

[email protected]

18801735029

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

A Prospective Randomized Phase II Trial of CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for Microsatellite Stable Locally Advanced Rectal Cancer (TORCH-iTNT)

Acronym: TORCH-iTNT

Important dates

Study start
2024
Primary completion
2026
Study completion
2028
First posted
Feb 28, 2024
Registry last updated
Apr 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.